Cannabidiol Patent Expiration
Cannabidiol is Used for reducing convulsive seizure frequency in patients with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. It was first introduced by Jazz Pharmaceuticals Research Uk Ltd
Cannabidiol Patents
Given below is the list of patents protecting Cannabidiol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Epidiolex | US12661365 | Use Of Cannabidiol In The Treatment Of Epilepsy | Sep 24, 2042 | Jazz Pharms Res |
| Epidiolex | US11160795 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | Mar 01, 2041 | Jazz Pharms Res |
| Epidiolex | US11406623 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | Mar 01, 2041 | Jazz Pharms Res |
| Epidiolex | US12102619 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | Mar 01, 2041 | Jazz Pharms Res |
| Epidiolex | US11207292 | Cannabidiol preparations and its uses | Apr 26, 2039 | Jazz Pharms Res |
| Epidiolex | US11865102 | Cannabidiol preparations and its uses | Apr 26, 2039 | Jazz Pharms Res |
| Epidiolex | US10918608 | Use of cannabidiol in the treatment of epilepsy | Oct 13, 2035 | Jazz Pharms Res |
| Epidiolex | US11065209 | Use of cannabidiol in the treatment of epilepsy | Oct 13, 2035 | Jazz Pharms Res |
| Epidiolex | US11096905 | Use of cannabinoids in the treatment of epilepsy | Oct 13, 2035 | Jazz Pharms Res |
| Epidiolex | US11400055 | Use of cannabidiol in the treatment of epilepsy | Oct 13, 2035 | Jazz Pharms Res |
| Epidiolex | US10092525 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US10111840 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US10137095 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US10603288 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US10709671 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US10709673 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US10709674 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US10849860 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US10966939 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US11154516 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US11311498 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US11357741 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US11446258 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US11633369 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US11701330 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US11766411 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US11963937 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US12064399 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US9949937 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US9956183 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US9956184 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US9956185 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US9956186 | Use of cannabinoids in the treatment of epilepsy | Jun 17, 2035 | Jazz Pharms Res |
| Epidiolex | US10195159 | Processes and apparatus for extraction of active substances and enriched extracts from natural products |
May 07, 2022
(Expired) | Jazz Pharms Res |
Cannabidiol's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on Cannabidiol:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Evaluation of Oral THC and CBD in Men and Women | University of California, Los Angeles | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Cannabis (THC vs. CBD) in Multiple Sclerosis | University of Calgary | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder | Centre for Addiction and Mental Health | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury | University of Wisconsin, Madison | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Study Testing the Safety and Effects of Single Doses of S1-221 in Healthy Volunteers | Delphian Therapeutics Australia Pty, Ltd | NA |
COMPLETED
(Sep 1, 2026)
| PHASE1 |
| Study of Cannabidiol and Neuroimaging on Stress | Icahn School of Medicine at Mount Sinai | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| The Pharmacokinetics of a Hemp-Based Topical Product | Johns Hopkins University | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome | Johns Hopkins University | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Oral and Topical Phytocannabinoids for Psoriasis | Federal University of Latin American Integration | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| RCT of CBD for Anxiety in Advanced Breast Cancer | Dana-Farber Cancer Institute | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome | Harmony Biosciences Management, Inc. | NA |
COMPLETED
(Aug 1, 2026)
| PHASE3 |
| Life's End Benefits of cannaBidiol and tetrahYdrocannabinol | University of Southern California | NA |
COMPLETED
(Aug 1, 2026)
| PHASE2 |
| Role of CBD in Improving Alexithymia | University of California, San Diego | NA |
TERMINATED
(Aug 1, 2026)
| PHASE2 |
| Topical CBD Scar Healing Study | University of Oklahoma | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals With Fragile-X Syndrome | Université de Sherbrooke | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Warrior CARE: Cannabis Behavioral Health | Wayne State University | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1, PHASE2 |
| Unique Treatment of Oncology Pain in Advanced Cancer | ZYUS Life Sciences Inc. | NA |
COMPLETED
(Aug 1, 2026)
| PHASE2 |
| Stratification and Treatment in Early Psychosis Study - ENHANCE | University of Oxford | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Effects of Cannabidiol on Stress and Nicotine Withdrawal | Johns Hopkins University | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving | Johns Hopkins University | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE2, PHASE3 |
| A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures | Jazz Pharmaceuticals | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Cannabidiol for Pain Relief of Patients With End-stage mCRPC | Regionshospital Nordjylland | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| A Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis | University of Florida | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Full-Spectrum Cannabis Extract for Chronic Pain and Bone Health Biomarkers in Women | Associação Pan-Americana Multidisciplinar de Endocanabinologia | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee | Steven E Harte, PhD | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults | University of Nebraska | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype | Tiffany J. Braley, MD, MS | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Cannabidiol Medication Intervention Trial | Sunnybrook Health Sciences Centre | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis | Mclean Hospital | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer | City of Hope Medical Center | NA |
SUSPENDED
(Jul 1, 2026)
| PHASE2 |
| Combined THC and CBD for OUD and Chronic Pain | Yale University | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| CBD Supplementation in Brazilian Jiu-Jitsu Athletes | Associação Pan-Americana Multidisciplinar de Endocanabinologia | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE2, PHASE3 |
| Cannabidiol Oil for Treatment-Resistant Major Depression | Universidade do Sul de Santa Catarina | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1, PHASE2 |
| Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain | Staci Gruber, Ph.D. | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1, PHASE2 |
| Epidiolex in Obsessive Compulsive Disorder and Related Disorders | University of Chicago | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |
| Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis | NYU Langone Health | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2, PHASE3 |
| Cannabidiol for Reducing Drinking in Alcohol Use Disorder | Hôpital le Vinatier | NA |
TERMINATED
(Jun 1, 2026)
| PHASE2 |
| Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis | Cardiol Therapeutics Inc. | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |
| Alcohol Use Disorder and Cannabidiol | University of Colorado, Denver | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2, PHASE3 |
| CANnabinoids in Pediatric ONCology | University of Manitoba | NA |
RECRUITING
(Jun 1, 2026)
| PHASE1, PHASE2 |
| CBD for Individuals at Risk for Alzheimer's Disease | University of Colorado, Denver | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2 |
| Study of Cannabidiol in Sanfilippo Syndrome | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2, PHASE3 |
| Efficacy and Tolerance of THC 25: CBD 25 in Patients With Severe Pruritus: a Multicenter, Double-blind, Randomized, Placebo-controlled Study | University Hospital, Brest | NA |
NOT YET RECRUITING
(Jun 1, 2026)
| PHASE2 |
| CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children | University of Manitoba | NA |
NOT YET RECRUITING
(Jun 1, 2026)
| PHASE2 |
| Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use | University of Colorado, Boulder | NA |
NOT YET RECRUITING
(Jun 1, 2026)
| PHASE2 |
| Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials | UMC Utrecht | NA |
RECRUITING
(Jun 1, 2026)
| PHASE3 |
| Cannabidiol and Prolonged Exposure | VA Office of Research and Development | NA |
COMPLETED
(May 1, 2026)
| PHASE2 |
| Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS | Zynerba Pharmaceuticals, Inc. | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE2, PHASE3 |
| Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT | McMaster University | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |
| Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus | Indiana University | NA |
COMPLETED
(May 1, 2026)
| PHASE1 |
| MIVetsCan: Cannabidiol (CBD)-Care Trial | Kevin Boehnke | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |
| CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy | Milton S. Hershey Medical Center | NA |
RECRUITING
(May 1, 2026)
| PHASE1 |
| Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD) | Universidade do Sul de Santa Catarina | NA |
RECRUITING
(May 1, 2026)
| PHASE1, PHASE2 |
| nVNS, CBD, and SoC for Persistent Post-Traumatic Headache | American Society of Pain and Neuroscience, Inc. | NA |
NOT YET RECRUITING
(May 1, 2026)
| PHASE2 |
| Cannabis for the Prophylactic Treatment of Migraine | University of Calgary | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |
| Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV | University of California, San Diego | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |
| Fenfluramine for Adult Dravet Patients | University Health Network, Toronto | NA |
TERMINATED
(Apr 1, 2026)
| PHASE3 |
| Cannabidiol for Reducing Cigarette Use | University of California, Los Angeles | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |
| Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty | Chad Brummett | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |
| CBD for Pain Following Orthopedic Shoulder Surgery | The Methodist Hospital Research Institute | NA |
RECRUITING
(Apr 1, 2026)
| PHASE1, PHASE2 |
| Cannabidiol and Cannabis Concentrate Users | University of Colorado, Denver | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |
| Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study | Florida A&M University | NA |
RECRUITING
(Apr 1, 2026)
| PHASE1, PHASE2 |
| Efficacy of Cannabidiol in the Management of Self-injuries in Children and Adolescents With Severe Neurodevelopmental Disorders. | Assistance Publique - Hôpitaux de Paris | NA |
NOT YET RECRUITING
(Apr 1, 2026)
| PHASE2 |
| CBD Knee Osteoarthritis Study | University of Tennessee | NA |
NOT YET RECRUITING
(Apr 1, 2026)
| PHASE2 |
| Sublingual Cannabidiol for Anxiety | Staci Gruber, Ph.D. | NA |
COMPLETED
(Mar 1, 2026)
| PHASE2 |
| PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product | Staci Gruber, Ph.D. | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2 |
| Evaluation of Smoked THC and CBD in Men and Women | University of California, Los Angeles | NA |
COMPLETED
(Mar 1, 2026)
| PHASE1 |
| Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis | Incannex Healthcare Ltd | NA |
TERMINATED
(Mar 1, 2026)
| PHASE2 |
| The Effectiveness of CBD and CBN in the Treatment of Facial Pain and Headache of Muscular Origin | Wroclaw Medical University | NA |
ENROLLING BY INVITATION
(Mar 1, 2026)
| PHASE2, PHASE3 |
| Use of CBD in the Treatment of Anxiety | University of Florida | NA |
ACTIVE NOT RECRUITING
(Mar 1, 2026)
| PHASE2 |
| Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder | Wayne State University | NA |
RECRUITING
(Mar 1, 2026)
| PHASE3 |
| Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden | National Cancer Institute, Naples | NA |
NOT YET RECRUITING
(Mar 1, 2026)
| PHASE2 |
| KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study | Helsinki University Central Hospital | NA |
NOT YET RECRUITING
(Mar 1, 2026)
| PHASE1 |